Bifantis As Promising Probiotic Treatment For Irritable Bowel Syndrome

Armen Hareyan's picture
Advertisement

Studies show inflammatory biomarkers return to normal levels, reduction in irritable bowel syndromesymptoms after treatment with Bifantis.

Two new review articles that cover therapeutic approaches to irritable bowel syndrome (IBS) in the July issue of Nutrition in Clinical Practice, cite growing evidence that probiotics, and specifically Bifidobacterium infantis 35624 (Bifantis®), are effective in helping manage IBS. Both articles point to data that suggest Bifantis (available in the U.S. only in supplement form, marketed as Align) – has anti-inflammatory properties that help normalize gut function at a cellular level.

In the first article, "Behavioral and Complementary Approaches for the Treatment of IBS," authors note that probiotic and IBS studies are "fraught with inconsistencies" but also note that there is "increasing evidence of efficacy" for probiotics . Two studies on Bifantis are cited. The first study evaluated patients randomly receiving Lactobacillus salivarius, Bifantis or placebo, and after eight weeks found that the patients receiving Bifantis had the greatest reduction in irritable bowel syndrome symptoms. The study also found that these patients experienced a reduction of inflammatory cytokines compared with those taking placebo .

Advertisement

The second study cited in the review article established the therapeutic dose for Bifantis in capsule form at 1 × 108 colony forming units as significantly superior to placebo and all other doses for improvement in abdominal pain, bloating, bowel dysfunction, straining, and gas at the end of the four week study .

"We think that imbalances in gut microflora lead to a chronic, low-level inflammation in the intestines and the presence of these inflammatory biomarkers in the bloodstream.

The overall impact of these circulating biomarkers is unclear, but it's been suggested that they could negatively impact healthy tissues," said Liam O'Mahony, the lead investigator of the inflammation study cited in the review article. "The Bifantis results not only have great implications for the treatment of digestive conditions, but offer researchers a potentially new path of exploration around inflammation-based diseases like arthritis."

The second review article, "Update on Irritable Bowel Syndrome and Gender Differences", which cites the same study by O'Mahony et al., notes that the "strain and type of probiotic used may be responsible for the degree and type of improvement."ii The article highlighted efficacy data from the O'Mahony study, noting that the patients receiving Bifantis experienced a reduction of IBS symptoms ranging from constipation, diarrhea and bloating for up to four weeks.

Advertisement